CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts

CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect i...

Descripción completa

Detalles Bibliográficos
Autores principales: Marangoni, E, Lecomte, N, Durand, L, de Pinieux, G, Decaudin, D, Chomienne, C, Smadja-Joffe, F, Poupon, M-F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661796/
https://www.ncbi.nlm.nih.gov/pubmed/19240712
http://dx.doi.org/10.1038/sj.bjc.6604953
_version_ 1782165823886983168
author Marangoni, E
Lecomte, N
Durand, L
de Pinieux, G
Decaudin, D
Chomienne, C
Smadja-Joffe, F
Poupon, M-F
author_facet Marangoni, E
Lecomte, N
Durand, L
de Pinieux, G
Decaudin, D
Chomienne, C
Smadja-Joffe, F
Poupon, M-F
author_sort Marangoni, E
collection PubMed
description CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx.
format Text
id pubmed-2661796
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-26617962010-03-24 CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts Marangoni, E Lecomte, N Durand, L de Pinieux, G Decaudin, D Chomienne, C Smadja-Joffe, F Poupon, M-F Br J Cancer Translational Therapeutics CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx. Nature Publishing Group 2009-03-24 2009-02-24 /pmc/articles/PMC2661796/ /pubmed/19240712 http://dx.doi.org/10.1038/sj.bjc.6604953 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Translational Therapeutics
Marangoni, E
Lecomte, N
Durand, L
de Pinieux, G
Decaudin, D
Chomienne, C
Smadja-Joffe, F
Poupon, M-F
CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
title CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
title_full CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
title_fullStr CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
title_full_unstemmed CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
title_short CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
title_sort cd44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661796/
https://www.ncbi.nlm.nih.gov/pubmed/19240712
http://dx.doi.org/10.1038/sj.bjc.6604953
work_keys_str_mv AT marangonie cd44targetingreducestumourgrowthandpreventspostchemotherapyrelapseofhumanbreastcancersxenografts
AT lecomten cd44targetingreducestumourgrowthandpreventspostchemotherapyrelapseofhumanbreastcancersxenografts
AT durandl cd44targetingreducestumourgrowthandpreventspostchemotherapyrelapseofhumanbreastcancersxenografts
AT depinieuxg cd44targetingreducestumourgrowthandpreventspostchemotherapyrelapseofhumanbreastcancersxenografts
AT decaudind cd44targetingreducestumourgrowthandpreventspostchemotherapyrelapseofhumanbreastcancersxenografts
AT chomiennec cd44targetingreducestumourgrowthandpreventspostchemotherapyrelapseofhumanbreastcancersxenografts
AT smadjajoffef cd44targetingreducestumourgrowthandpreventspostchemotherapyrelapseofhumanbreastcancersxenografts
AT pouponmf cd44targetingreducestumourgrowthandpreventspostchemotherapyrelapseofhumanbreastcancersxenografts

Ejemplares similares